Skip to main content

Innovative Approaches to Cholangiocarcinoma: Diagnosis, Treatment, and Multidisciplinary Care

32kviews
Editorial02 December 2025
Editorial: Innovative approaches to cholangiocarcinoma: diagnosis, treatment, and multidisciplinary care
Karol Rawicz-Pruszyński, Piero Boraschi and Lorenzo Fornaro

Biliary tract cancer (BTC) is a heterogenous group of malignancies, comprising intrahepatic, extrahepatic and perihilar cholangiocarcinoma, as well as gallbladder cancer.BTC is generally recognized as an aggressive disease, surgery representing the only potentially curative treatment. However, recurrence rates after resection remain high, with an even larger proportion of patients still presenting with unresectable or overtly metastatic disease at diagnosis [1]. In such cases, palliative systemic therapy is the mainstay of treatment [2]. Challenging issues in BTC management can be faced by clinicians during the entire course of the disease, from radiological and histopathological diagnosis, through molecular characterization, to treatment of the disease and palliation of symptoms. In recent years, several advances in the approach to such a difficult clinical scenario has been achieved [1,2]. In this research topic we aim to describe some of the most recent improvements in the diagnosis, prognostic classification and treatment of BTC.In particular, Liu et al. and Lang et al. provided intriguing insights into the identification of prognostic indicators in BTC. In their works, several routinely available parameters (correlated with the inflammatory, nutritional, and immune status of patients) have been either confirmed or identified as valuable markers, to stratify the whole patient population into different prognostic subgroups in different disease settings, beyond the conventional classification based on the site of tumor origin along the biliary tree. This could be of particular interest for clinicians, in order to personalize treatment approaches as well as follow up strategies, and could be implemented into future studies as stratification factors to properly assess treatment impact into different patient subsets [3]. Moreover, molecular characterization of BTC is gaining momentum in the oncology community, but the prognostic role of major biological alterations identified in BTC is still under investigation [4]: the ability to provide prognostic information by easily accessible parameters (such those described in the included articles) is therefore of relevance to ensure the best prognostic classification in different clinical situations.Other authors contributed with systematic review or original researches to the current debate about the role of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in BTC management. There is no doubt that the introduction of ICIs, such as durvalumab and pembrolizumab, into the treatment armamentarium against BTC has represented a major advancement in this disease [5]. However, optimization of ICI treatment is still far from its final goal, and head-to-head comparison between different agents has not been reported. Currently, the choice between different agents is mainly based on indirect comparisons of safety and efficacy data from trials with different designs

1,357 views

Prognostic Value of CRP-Albumin-Lymphocyte (CALLY) index in Patients with Intrahepatic Cholangiocarcinoma after Radical Resection
The aim of this study is to explore the prognostic value of CRP-Albumin-Lymphocyte (CALLY) index in patients undergoing radical resection of intrahepatic cholangiocarcinoma (ICC).: Retrospectively collected clinical data of 286 patients with ICC who underwent radical surgery at Shandong Provincial Hospital from July 2010 to July 2021. Univariate and multivariate analyses were used to evaluate the correlation between the CALLY index and overall survival (OS) and recurrence-free survival (RFS), and a nomogram prediction model was established based on the results. The accuracy of the model was evaluated using concordance index (C-index), calibration curves, decision curve analysis (DCA), and the receiver operating characteristic (ROC) curve was used to compare the prognostic value of the nomogram model with the TNM staging system.The optimal cut-off value of CALLY index was 1.81. In the training set, multifactorial Cox regression analysis showed that CALLY index <1.81 was an independent risk factor for OS and RFS (p<0.05). Compared to neutrophil-tolymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune inflammation index (SII), and modified Glasgow prognostic score (mGPS), CALLY index had a higher area under the curve (AUC). The nomogram established based on the results of multifactorial analysis demonstrated strong efficacy in survival prediction, and the ROC curve showed that the nomogram had a higher prognostic value than TNM staging.The CALLY index is independently associated with OS and RFS in patients after radical resection of ICC, and the nomogram model based on it shows significantly higher efficacy in predicting the long-term prognosis of patients after radical resection of ICC, and is more accurate than TNM staging.

3,265 views

15 citations

SYSTEMATIC REVIEW
8 April 2025
Preoperative glasgow prognostic score was an effective prognostic indicator in patients with biliary tract cancer
Rongqiang Liu, 6 more and Weixing Wang

2,887 views

7 citations

BackgroundThe addition of durvalumab or pembrolizumab to gemcitabine and cisplatin (GP) has been approved to statistically improve survival outcomes in patients with advanced biliary tract cancer. However, since the survival time was only prolonged by about two months, doubts have been raised. In this analysis, we aimed to evaluate the efficacy of combining durvalumab or pembrolizumab with GP chemotherapy.MethodsRecords were identified through a formal search of PubMed and Web of Science. The TOPAZ-1 and KEYNOTE-966 trials were definitively included. Patient-level overall survival (OS) and progression-free survival (PFS) data were reconstructed and analyzed using a one-stage approach.ResultsThe immunotherapy plus GP chemotherapy group showed superiority over the GP chemotherapy group (OS: HR 0.83, p < 0.001; PFS: HR 0.88, p = 0.009). The survival outcomes were similar between the durvalumab and pembrolizumab groups (OS: HR 1.02, p = 0.83; PFS: HR 0.95, p = 0.53). In the subgroup analysis, the gemcitabine-maintenance group significantly prolonged the OS compared to the gemcitabine-limited-to-8-cycles group (OS: HR 0.86, p = 0.007). Neither the durvalumab nor pembrolizumab groups statistically improved the OS compared to the gemcitabine-maintenance group. In contrast, the durvalumab and pembrolizumab groups significantly improved OS compared to the gemcitabine-limited-to-8-cycles group.ConclusionsBased on this mimic head-to-head analysis, we are convinced that durvalumab and pembrolizumab benefit patients with biliary tract cancer. However, despite the statistically significant differences, the moderate progress made in OS and PFS might still be considered inadequate. It is crucial for clinicians to identify the precise subgroup population that could benefit most from immunotherapy and develop more strategies for those who might not respond well to immunotherapy.

9,856 views

5 citations

Effect of immune checkpoint inhibitor time-of-day infusion on survival in advanced biliary tract cancer: a propensity score-matched analysis
ORIGINAL RESEARCH
18 December 2024
Effect of immune checkpoint inhibitor time-of-day infusion on survival in advanced biliary tract cancer: a propensity score-matched analysis
Yichen Zheng, 4 more and Ji Ma
BackgroundCircadian rhythms in the immune system and anti-tumor responses are underexplored in cancer immunotherapy. Despite the success of immune checkpoint inhibitors (ICIs) in treating advanced biliary tract cancers (BTCs), not all patients benefit. This study examined whether the timing of ICI administration affects outcomes in advanced BTC patients.MethodsWe included advanced BTC patients from West China Hospital of Sichuan University who received ≥2 ICI treatments from October 2019 to September 2023, with follow-up until May 2024. Primary outcome was overall survival (OS), with secondary outcomes including progression-free survival (PFS), objective response rate (ORR), and adverse events (AEs). Propensity score matching (1:2 ratio, caliper width 0.1) mitigated confounding factors. Cox proportional hazards regression analyzed the impact of ICI timing (post-16:30) on OS and PFS. Chi-square test assessed ORR and AE differences.ResultsAmong 221 patients, 51 received ≥20% of ICIs after 16:30; 170 received <20%. Post-matching, 49 late-infusion patients had significantly shorter OS (median 10.1 vs. 14.5 months, HR=1.80, P=0.012) compared to 90 early-infusion patients. Pre-matching, late-infusion patients also had shorter OS (median 9.8 vs. 13.7 months, HR=1.68, P=0.010) and PFS (median 4.9 vs. 8.1 months, HR=1.62, P=0.006). Multivariate analysis confirmed these results. No significant differences were found in ORR (χ^2 = 1.53, P=0.215) or AEs (all P>0.050). Sensitivity analyses supported these findings.ConclusionTiming of ICI administration affects efficacy in advanced BTC, with pre-16:30 infusions linked to better survival. Larger, prospective studies are needed to validate these results.

4,609 views

20 citations